Canaccord raised the firm’s price target on 10x Genomics (TXG) to $20 from $19 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026, albeit they do see some risk for 10x Genomics shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target raised to $18 from $15 at BofA
- 10x Genomics price target raised to $22 from $17 at Barclays
- 10x Genomics downgraded to Neutral from Buy at Citi
- Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls
- 10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley